Madrigal Pharmaceuticals shares are trading higher after the company announced the rolling submission of a New Drug Application to the FDA seeking accelerated approval of resmetirom for the treatment of NASH with liver fibrosis.
Portfolio Pulse from Benzinga Newsdesk
Madrigal Pharmaceuticals has announced the rolling submission of a New Drug Application to the FDA for accelerated approval of resmetirom, a treatment for NASH with liver fibrosis. This has led to a rise in the company's share prices.
June 30, 2023 | 3:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Madrigal Pharmaceuticals' shares are trading higher after the company announced the submission of a New Drug Application to the FDA for resmetirom. This could potentially lead to increased revenues if the drug is approved.
The announcement of the New Drug Application submission is a positive development for Madrigal Pharmaceuticals. If the FDA approves the drug, it could lead to increased revenues for the company, which is likely why the share prices have risen. However, the final impact will depend on the FDA's decision.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100